Recent Developments in the Treatment of Diabetes

  • Cliff J. Bailey
  • Peter R. Flatt


Diabetes mellitus is a growing health problem throughout the world. In the United Kingdom alone there are probably more than one million sufferers, many of whom rely on daily injections of insulin. There have been several important developments recently in the treatment of diabetes. Particularly significant has been the coming of age of human insulin.


Human Insulin Hepatic Glucose Production Oral Hypoglycaemic Agent Induce Weight Gain Oral Hypoglycaemic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Diabetes Data Group (1979). Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28, 1039–1057CrossRefGoogle Scholar
  2. 2.
    DeForonzo, R. A., Ferrannini, E. and Koivisto, Y. (1983). New concepts in the pathogenesis and treatment of non-insulin dependent diabetes mellitus. Am. J. Med., 74, Suppl. 1, 52–81CrossRefGoogle Scholar
  3. 3.
    Lebovitz, H. E. and Feinglos, M. N. (1983). The oral hypoglycaemic agents. In Diabetes Mellitus, Theory and Practice, 3rd edn (Eds. Ellenberg, M. and Rifkin, H.), pp.591–610, New York, Medical Examination Publishing Co.Google Scholar
  4. 4.
    Keen, H. and Jarrett, J. (Eds.). Complications of Diabetes, 2nd edn, London, Edward ArnoldGoogle Scholar
  5. 5.
    World Health Organization Expert Committee on Diabetes mellitus. Second Report, Technical Report Series No. 646, Geneva, World Health Organization, 1980Google Scholar
  6. 6.
    British National Formulary, No. 10. London: British Medical Association and The Pharmaceutical Society of Great Britain, 1985Google Scholar
  7. 7.
    Lockwood, D. H., Gerich, J. E. and Goldfine, I. (Eds.) (1984). Symposium on effects of oral hypoglycaemic agents on receptor and postreceptor actions of insulin. Diabetes Care, 7, Suppl. 1, 1–125Google Scholar
  8. 8.
    Hermann, L. S. (1979). Metformin: a review of its pharmacological properties and therapeutic use. Diab. Metab., 5, 233–245Google Scholar
  9. 9.
    Bailey, C. J. (1985). The antihyperglycaemic action of metformin. In Diabetes and Metformin, Krans, H. M. J. (Ed.), Royal Society of Medicine Int. Congr. Series No. 79, pp. 17–26, London, Royal Society of MedicineGoogle Scholar
  10. 10.
    Bailey, C. J., Lord, J. M. and Atkins, T. W. (1985). The insulin receptor and diabetes. In Recent Advances in Diabetes, Vol. 1, Nattrass, M. and Santiago, J. V. (Eds.), pp.27–44, Edinburgh, Churchill LivingstoneGoogle Scholar
  11. 11.
    Bailey, C. J. and Flatt, P. R. (1986). Animal models of diabetes. In Recent Advances in Diabetes, Vol. 2, Nattrass, M. (Ed.), Edinburgh, Churchill LivingstoneGoogle Scholar
  12. 12.
    Bailey, C. J., Day, C. and Leatherdale, B. A. (1986). Traditional plant remedies for diabetes. Diabetic Med., 3, 185–186CrossRefGoogle Scholar
  13. 13.
    Kean, E. A. and Pogson, C. I. (1979). Inhibition of gluconeogenesis in isolated rat liver cells by methylenecyclopropylpyruvate (ketohypoglycin). Biochem. J., 182, 789–796CrossRefGoogle Scholar
  14. 14.
    Day, C. (1986). Guar gum. International Industrial Biotechnology, 6, 3Google Scholar
  15. 15.
    Doi, K., Matsuura, M., Kawara, A. and Baba, S. (1979). Treatment of diabetes with glucomannan (Konjac mannan). Lancet, i, 987–988CrossRefGoogle Scholar
  16. 16.
    Aubell, R., Boehme, K. and Berchtold, P. (1983). Blood glucose concentrations and glycosurea during and after one year of acarbose therapy. Arzneimittelforsch, Drug Res., 33, 1314–1318Google Scholar
  17. 17.
    Hosokawa, T., Ando, K. and Tamura, G. (1985). An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/db. Diabetes, 34, 267–274CrossRefGoogle Scholar
  18. 18.
    Wolf, H. P. O., Eistetter, K. and Ludwig, G. (1982). Phenylalkyloxirane carboxylic acids, a new class of hypoglycaemic, and hypoketonaemic effects of sodium 2-5(4-chlorophenyl)-pentyl-oxirane-2-carboxylate (B 807-27) in fasted animals. Diabetologia, 22, 456–463CrossRefGoogle Scholar
  19. 19.
    Carroll, M. J., Lister, C. A., Sennitt, M. V., Strewart-Long, N. and Cawthorne, M. A. (1985). Improved glycaemic control in C57BL/KsJ (db/db) mice after treatment with the thermogenic β-adrenoceptor agonist, BRL 26830. Diabetes, 34, 1198–1204CrossRefGoogle Scholar
  20. 20.
    Diani, A. R., Peterson, T., Sawada, G. A., Wyse, B. M., Gilchrist, B. J., Hearron, A. E. and Chang, A. Y. (1984). Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J ob/ob and C57BL/KsJ db/db mice. Diabetologia, 27, 225–234Google Scholar
  21. 21.
    Ribes, G., Trimble, E. K., Blayac, J. P., Wollheim, C. B., Puech, R. and Loubatieres-Mariani, M. M. (1981). Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia, 20, 501–505CrossRefGoogle Scholar
  22. 22.
    Verdy, M., Charbonneay, L., Verdy, L., Belonger, R., Boite, E. and Chaisson, J. L. (1983). Fenfluramine in the treatment of non-insulin dependent diabetics: hypoglycaemic versus anorectic effect. Int. J. Obesity, 7, 289–297Google Scholar
  23. 23.
    Oellerich, M. and Haeckel, R. (1980). Hydrazonopropionic acid, a new class of hypoglycaemic substances. Horm. Metab. Res., 12, 182–189CrossRefGoogle Scholar
  24. 24.
    Tutwiler, G. F., Tuman, R. W., Wallace, N. H. and Zawalich, W. (1984). Studies in isolated rat islets with linogliride fumarate (LIN), a new orally effective hypoglycaemic agent. Excerpta Medica Int. Congr., Series No. 652, p. 1434, Amsterdam, Excerpta MedicaGoogle Scholar
  25. 25.
    Caprio, S., Ray, T. K., Boden, G., Smith, R. H., Mozzoii, M. A., Hoeldtke, R. D., Shuman, C. R. and Owen, O. E. (1982). Mebendazole increases insulin secretion: improvement of insulin secretion in diabetic patients during mebendazole administration. Excerpta Medica Int. Congr., Series No. 577, p.200, Amsterdam, Excerpta MedicaGoogle Scholar
  26. 26.
    Tutwiler, G. F., Kirsch, T., Mohrbacher, R. J. and Ho, W. (1978). Pharmacologic profile of methyl-2-tetradecylglycidate (McN-3716), an orally effective hypoglycaemic agent. Metabolism, 27, 1539–1556CrossRefGoogle Scholar
  27. 27.
    Lee, S. M., Tutwiler, G., Bressler, R. and Kircher, C. H. (1982). Metabolic control and prevention of nephropathy by 2-tetradecylglycidate in the diabetic mouse (db/db). Diabetes, 31, 12–18CrossRefGoogle Scholar
  28. 28.
    Zawalick, W. S., Weill, V. A. and Matschinsky, F. M. (1980). Pirogliride: a new oral hypoglycaemic drug which accelerates glucose usage and insulin secretion by islets of Langerhans. Diabetes, 29, 410–412CrossRefGoogle Scholar
  29. 29.
    Iwai, H., Inamasu, M., Totsuka, T., Shimazaki, T., Morita, T. and Takeyama, S. (1983). Hypoglycaemic activity of 1-α (3,4-dimethoxyphenethyl-aminomethyl)-2-hydroxybenzylalcohol-1,2-fumarate (TA-078) in the mouse, rat and dog. Biochem. Pharmacol., 32, 849–855CrossRefGoogle Scholar
  30. 30.
    Bailey, C. J., Day, C., Turner, S. L. and Leatherdale, B. A. (1985). Cerasee, a traditional treatment for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetes Res., 2, 81–84Google Scholar
  31. 31.
    Azad Khan, A. K., Akhtar, S. and Mahtab, H. (1980). Treatment of diabetes mellitus with Coccinia indica. Brit. Med. J., 280, 1044CrossRefGoogle Scholar
  32. 32.
    Al-Awadi, F. M., Augelo-Khattar, M. and Gumaa, K. A. (1985). On the mechanism of the hypoglycaemic effect of a plant extract. Diabetologia, 28, 432–434CrossRefGoogle Scholar
  33. 33.
    Ajabnoor, M. A., Al-Yahya, M. A., Tariq, M. and Jayyab, A. A. (1984). Antidiabetic activity of Teucrium oliverianum. Fitoterapia, 55, 227–230Google Scholar
  34. 34.
    Ribes, G., Sauvaire, Y., Baccou, J. C., Valette, G., Chenon, D., Trimble, E. R. and Loubatieres-Mariani, M. M. (1984). Effects of fenugreek seeds on endocrine pancreatic secretions in dogs. Ann. Nutr. Metab., 28, 37–43CrossRefGoogle Scholar


  1. 1.
    Alberti, K. G. M. M. and Krall, L. P. (Eds.) (1985). The Diabetes Annual, Vol. 1, Elsevier, AmsterdamGoogle Scholar
  2. 2.
    Clark, A. J. L. et al. (1982). Biosynthetic human insulin in the treatment of diabetes. Lancet, ii, 354–357CrossRefGoogle Scholar
  3. 3.
    Goldstein, D. E. et al. (1982). Clinical application of glycosylated haemoglobin measurements. Diabetes, 31, Suppl. 3, 71–78CrossRefGoogle Scholar
  4. 4.
    Hansen, B. et al. (1982). New approaches to therapy and diagnosis of diabetes. Diabetologia, 22, 61–67CrossRefGoogle Scholar
  5. 5.
    Nattrass, M. and Santiago, J. V. (Eds.) (1984). Recent Advances in Diabetes, Vol. 1, Churchill Livingstone, EdinburghGoogle Scholar
  6. 6.
    Pickup, J. (1986). Human insulin. Brit. Med. J., 292, 155–157CrossRefGoogle Scholar

Copyright information

© The Editor and the Contributors 1988

Authors and Affiliations

  • Cliff J. Bailey
  • Peter R. Flatt

There are no affiliations available

Personalised recommendations